Vaccines Market - Global Forecast to 2030
商品番号 : SMB-10881
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年9月 |
| ページ数 | 450 |
| 図表数 | 498 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
ワクチン市場 – 技術（結合型、組み換え型、不活化型、生弱毒化型、ウイルスベクター、mRNA）、タイプ（一価、多価）、疾患（肺炎球菌、インフルエンザ、肝炎、MMR、RSウイルス）、投与経路（筋肉内、皮下、経口） – 2030年までの世界予測
ワクチン市場は、2025年の504.6億米ドルから2030年には636.6億米ドルに達し、予測期間中に年平均成長率（CAGR）4.8%で成長すると予測されています。感染症の高発生率、ワクチン技術の革新、ワクチン開発に対する政府の支援と多額の資金提供、ワクチン接種イニシアチブの増加、革新的な製品への投資と発売への注力といった要因が、ワクチン市場の成長を牽引しています。
本調査レポートは、ワクチン市場を技術別（結合型ワクチン、組換え型ワクチン、不活化・サブユニットワクチン、生弱毒化ワクチン、トキソイドワクチン、ウイルスベクターワクチン、mRNAワクチン、その他）、種類別（一価ワクチン、多価ワクチン）、適応症別（肺炎球菌感染症、インフルエンザ、混合ワクチン、HPV、髄膜炎菌感染症、帯状疱疹、ロタウイルス、MMR、水痘、肝炎、三種混合ワクチン（DTP）、ポリオ、RSA、その他）、投与経路別（筋肉内・皮下注射、経口、その他）、エンドユーザー別（小児用ワクチン、成人用ワクチン）、地域別（北米、欧州、アジア太平洋、ラテンアメリカ、中東、アフリカ）に分類しています。本レポートは、ワクチン市場の成長に影響を与える主要な要因（推進要因、課題、機会、制約など）に関する詳細な情報を提供しています。主要業界プレーヤーの包括的な分析を実施し、事業概要、製品ポートフォリオ、主要戦略（協業、パートナーシップ、事業拡大、契約、買収、ワクチン市場に関連する最近の動向など）に関する洞察を提供しています。本レポートには、ワクチン市場エコシステムにおける主要プレーヤーと新興企業の競合分析が含まれています。このレポートでは、市場の成長を形作る推進要因、制約、課題、機会などの主要な要因についても詳述するほか、主要な業界プレーヤーのソリューション、製品、最近の製品発売、合併、買収、新興市場のトレンドエコシステムの詳細なレビューも行っています。
本レポートは、ワクチン市場の包括的な概要を提供します。技術、種類、適応症、投与経路、エンドユーザー、地域など、様々なセグメントにおける市場の規模と将来の成長機会を評価することを目的としています。また、主要市場プレーヤーの企業概要、最近の動向、主要な市場戦略など、詳細な競合分析も掲載しています。
The vaccines market is expected to reach 63.66 billion USD in 2030, up from 50.46 billion USD in 2025, growing at a CAGR of 4.8% during the forecast period. Factors such as the high incidence of contagious diseases, innovation in vaccine technology, government support and substantial funding for vaccine development, increasing vaccination initiatives, and a strong focus on investing in and launching innovative products are driving this growth vaccines.
In 2024, by disease indication, the pneumococcal segment accounted for the largest share of the vaccines market.
Based on disease indication, the vaccines market is segmented into combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, and other disease indications. In 2022, the pneumococcal segment held the largest share of the vaccines market. This is due to several key factors: a rising incidence of pneumococcal infections worldwide; increased government funding for vaccination programs; and heightened public awareness of the serious health risks associated with pneumococcal-related complications such as pneumonia, meningitis, and bloodstream infections. Additionally, ongoing innovation and the development of next-generation pneumococcal vaccines, such as the recently approved 20-valent and 21-valent conjugate vaccines, are expanding immunization options, further boosting market growth and public health benefits outcomes.
In 2024, by type, the multivalent vaccines segment accounted for the largest share of the vaccines market.
The vaccines market is divided into monovalent vaccines and multivalent vaccines, based on type. In 2024, the multivalent vaccines segment held the largest portion of the Vaccines market. This dominance comes from the ability of multivalent vaccines to provide protection against multiple diseases with a single dose—simplifying immunization by reducing the number of injections needed, which increases patient compliance and decreases logistical challenges. Additionally, the growing prevalence of diseases that require broad-spectrum immunity, such as respiratory infections and certain cancers, has increased demand for these vaccines. Further supporting this trend are technological advances and increased investment in efficient manufacturing of multivalent vaccines, enabling larger and faster production. Governments and healthcare providers in regions with limited healthcare access particularly favor them because simplified vaccination schedules improve coverage and boost public health outcomes.
In 2024, the Asia Pacific was the fastest growing region in the Vaccines market.
The vaccines market region is divided into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa. The Asia Pacific region is expected to grow at a significant CAGR during the forecast period. This increase is driven by greater public health awareness, expanding national immunization programs, and increased government investment in healthcare infrastructure. Supporting these efforts are public–private partnerships, international collaborations aimed at improving vaccine equity, and technological advancements that enable advanced vaccine development and more affordable production. Additionally, the region’s large and growing populations, especially in countries such as China and India, present a substantial target market for both established and new vaccines. These factors highlight the Asia Pacific’s leadership in the vaccine industry market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
- By Designation: C-level Executives – 55%, Directors- 20%, and Others- 25%
- By Region: North America -35%, Europe – 25%, Asia Pacific -20%, Latin America -10%, the Middle East & Africa- 10%
GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E. Limited (India), Bharat Biotech (India), Novavax (US), Inovio Pharmaceuticals (US), Sinovac (China), Incepta Pharmaceuticals (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), Bio Farma (Indonesia), FSUE NPO Microgen (Russia), Zhi fei Biological (China), Indian Immunologicals Ltd (India) are some of the key companies offering Vaccines.
Research Coverage
This research report categorizes the Vaccines market by technology (conjugate vaccine, recombinant vaccine, inactivated & subunit vaccine, live attenuated vaccine, toxoid vaccine, viral vector vaccine, mRNA vaccine, and other vaccines), type (monovalent vaccines, multivalent vaccines), indication (pneumococcal disease, influenza, combination vaccine, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, RSA, other disease indications), route of administration (intramuscular & subcutaneous, oral, other routes), end user (pediatric vaccines, adult vaccines), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the vaccines market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, product portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments related to the vaccines market. Competitive analysis of top players and upcoming startups within the vaccines market ecosystem is included in this report. The report also details primary factors like drivers, restraints, challenges, and opportunities shaping the market growth, along with an in-depth review of key industry players’ solutions, products, recent product launches, mergers, acquisitions, and emerging market trends ecosystem.
Key Benefits of Buying the Report
This report offers a comprehensive overview of the Vaccines market. It aims to assess the size and future growth opportunities of the market across various segments, such as technology, type, indication, route of administration, end user, and region. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies.
The report provides insights into the following pointers:
Analysis of key drivers (strong emphasis on investment and launch of novel vaccines, rising prevalence of infectious disease, expanding immunization programs, advancements in vaccine technology and robust government support & funding for the development of vaccines), restraints (High development cost, patent expiry ), opportunities (Increased focus on therapeutic vaccines, robust & strong pipeline) and challenges (Stringent regulatory processes, vaccine supply shortage, frequent product recall)
- Product Development/Innovation: Detailed insights on newly launched Products, and technological assessment of the Vaccines market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the Vaccines market across varied regions.
- Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the Vaccines market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E. Limited (India), Bharat Biotech (India), Novavax (US), Inovio Pharmaceuticals (US), Sinovac (China), Incepta Pharmaceuticals (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), Bio Farma (Indonesia), FSUE NPO Microgen (Russia), Zhi fei Biological (China), Indian Immunologicals Ltd (India), among others, in the vaccines market. The report also helps stakeholders understand the trends of the vaccines market and provides information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been conducted to offer insights into their key strategies, product launches and approvals, pipeline developments, acquisitions, partnerships, collaborations, recent activities, investments, and funding activities, brand and product comparisons, vendor evaluations, and financial metrics of the vaccines sector market.
Table of Contents
1 INTRODUCTION 38
1.1 STUDY OBJECTIVES 38
1.2 MARKET DEFINITION 38
1.3 STUDY SCOPE 39
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 39
1.3.2 INCLUSIONS & EXCLUSIONS 40
1.3.3 YEARS CONSIDERED 40
1.3.4 CURRENCY CONSIDERED 41
1.4 STAKEHOLDERS 41
1.5 SUMMARY OF CHANGES 41
2 RESEARCH METHODOLOGY 43
2.1 RESEARCH DATA 43
2.1.1 SECONDARY DATA 44
2.1.1.1 Key sources of secondary data 44
2.1.1.2 Key objectives of secondary research 44
2.1.2 PRIMARY DATA 45
2.1.2.1 Breakdown of primaries 45
2.1.2.2 Key objectives of primary research 46
2.2 MARKET SIZE ESTIMATION 46
2.2.1 GLOBAL MARKET SIZE ESTIMATION, 2024 46
2.2.1.1 Company revenue analysis (bottom-up approach) 47
2.2.1.2 MarketsandMarkets repository analysis 48
2.2.1.3 Secondary analysis 48
2.2.1.4 Bottom-up approach (disease indication-based analysis) 49
2.2.1.5 Primary research 49
2.2.1.5.1 Insights from primary sources 50
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 50
2.3 MARKET GROWTH RATE PROJECTIONS 52
2.4 DATA TRIANGULATION 55
2.5 STUDY ASSUMPTIONS 56
2.6 RESEARCH LIMITATIONS 57
2.7 RISK ANALYSIS 57
3 EXECUTIVE SUMMARY 58
3.1 KEY INSIGHTS & MARKET HIGHLIGHTS 58
3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS IN VACCINES MARKET 64
3.3 DISRUPTIVE TRENDS SHAPING VACCINES MARKET 64
3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 65
4 PREMIUM INSIGHTS 66
4.1 GLOBAL VACCINES MARKET SNAPSHOT 66
4.2 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TYPE AND COUNTRY, 2024 67
4.3 VACCINES MARKET (EXCLUDING COVID-19 VACCINES): GEOGRAPHIC GROWTH OPPORTUNITIES 68
4.4 UNMET NEEDS & WHITE SPACES 68
4.5 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES 69
4.6 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS 70
4.7 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 71
4.8 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 71
5 MARKET OVERVIEW 73
5.1 INTRODUCTION 73
5.2 MARKET DYNAMICS 73
5.2.1 DRIVERS 74
5.2.1.1 Focus on vaccine development and launches 74
5.2.1.2 Rising prevalence of infectious diseases 75
5.2.1.3 Increasing immunization programs 76
5.2.1.4 Advancements in vaccine technology 77
5.2.1.5 Government support and funding for vaccine development 78
5.2.2 RESTRAINTS 79
5.2.2.1 High cost of vaccine development 79
5.2.3 OPPORTUNITIES 82
5.2.3.1 Rising focus on therapeutic vaccines 82
5.2.3.2 Extensive R&D for vaccines and increased investments in
clinical trials 84
5.2.4 CHALLENGES 85
5.2.4.1 Stringent regulatory processes 85
5.2.4.2 Product recalls 85
6 INDUSTRY TRENDS 87
6.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 87
6.2 PRICING ANALYSIS 87
6.2.1 AVERAGE SELLING PRICE TREND OF VACCINES, BY KEY PLAYER, 2023–2025 88
6.2.2 AVERAGE SELLING PRICE TREND OF VACCINES, BY DISEASE INDICATION, 2023–2025 91
6.2.3 AVERAGE SELLING PRICE TREND OF VACCINES, BY REGION, 2021–2023 91
6.3 TECHNOLOGY ANALYSIS 94
6.3.1 KEY TECHNOLOGIES 94
6.3.1.1 Recombinant technology 94
6.3.1.2 Conjugation technology 94
6.3.1.3 Viral vector technology 95
6.3.2 COMPLEMENTARY TECHNOLOGIES 95
6.3.2.1 Encapsulation & delivery technology 95
6.3.2.2 Automation & control 95
6.3.2.3 AI & machine learning for vaccine design 95
6.3.3 ADJACENT TECHNOLOGIES 96
6.3.3.1 Single-use technology 96
6.3.3.2 Cell line development 96
6.4 VALUE CHAIN ANALYSIS 96
6.5 PIPELINE ANALYSIS 98
6.5.1 VACCINES MARKET: CLINICAL TRIALS, BY PHASE 98
6.5.2 VACCINES MARKET: CLINICAL TRIALS, BY DISEASE INDICATION 98
6.5.3 VACCINES MARKET: PHASE 2/3 CLINICAL TRIALS, BY COMPANY 105
6.6 ECOSYSTEM ANALYSIS 107
6.6.1 VACCINES MARKET: ROLE IN ECOSYSTEM 107
6.7 REGULATORY ANALYSIS 108
6.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 109
6.7.2 REGULATORY FRAMEWORK 112
6.7.2.1 North America 112
6.7.2.2 Europe 112
6.7.2.3 Asia Pacific 113
6.7.2.4 Latin America 113
6.7.2.5 Middle East & Africa 113
6.7.3 REGULATORY CHALLENGES IN VACCINES MARKET 114
6.8 TRADE ANALYSIS 114
6.8.1 IMPORT DATA (HS CODE 300220) 114
6.8.2 EXPORT DATA (HS CODE 300220) 116
6.9 PORTER’S FIVE FORCES ANALYSIS 118
6.9.1 THREAT OF NEW ENTRANTS 119
6.9.2 THREAT OF SUBSTITUTES 119
6.9.3 BARGAINING POWER OF SUPPLIERS 119
6.9.4 BARGAINING POWER OF BUYERS 119
6.9.5 INTENSITY OF COMPETITIVE RIVALRY 120
6.10 PATENT ANALYSIS 120
6.10.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR VACCINE PATENTS, 2014–2024 121
6.11 KEY CONFERENCES & EVENTS, 2025–2026 123
6.12 KEY STAKEHOLDERS & BUYING CRITERIA 124
6.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 124
6.12.2 KEY BUYING CRITERIA 125
6.13 INVESTMENT & FUNDING SCENARIO 126
6.14 IMPACT OF AI/GENERATIVE AI ON VACCINES MARKET 127
6.14.1 INTRODUCTION 127
6.14.2 MARKET POTENTIAL OF AI IN VACCINES MARKET 127
6.14.3 AI USE CASES 128
6.14.4 KEY COMPANIES IMPLEMENTING AI 128
6.14.5 FUTURE OF GENERATIVE AI IN VACCINES ECOSYSTEM 129
6.15 IMPACT OF 2025 US TARIFFS ON VACCINES MARKET 129
6.15.1 INTRODUCTION 129
6.15.2 KEY TARIFF RATES 129
6.15.3 PRICE IMPACT ANALYSIS 130
6.15.4 IMPACT ON COUNTRY/REGION 131
6.15.4.1 US 131
6.15.4.2 Europe 131
6.15.4.3 Asia Pacific 131
6.15.5 IMPACT ON END-USE INDUSTRIES 132
6.15.5.1 Public health & government bodies 132
6.15.5.2 Healthcare providers & institutions 132
6.16 VACCINE PROCUREMENT DATA 133
6.16.1 NUMBER OF VACCINES DELIVERED BY UNICEF, 2023–2025 133
6.16.2 WHO: VACCINE PURCHASE DATABASE, 2021–2023 134
6.17 VACCINE MANUFACTURING PROCESS 136
6.17.1 OVERVIEW 136
6.17.1.1 R&D and process development 136
6.17.1.2 Upstream production (antigen generation) 137
6.17.1.3 Downstream processing 137
6.17.1.4 Formulation & fill-finish 137
6.17.1.5 Quality control & regulatory release 137
6.17.1.6 Packaging, cold chain, and distribution 137
6.17.2 MANUFACTURING MODELS & CAPACITY DYNAMICS 137
7 VACCINES MARKET, BY DISEASE INDICATION 139
7.1 INTRODUCTION 140
7.2 PNEUMOCOCCAL DISEASE 141
7.2.1 INCREASING INCIDENCE OF PNEUMONIA IN CHILDREN TO DRIVE MARKET 141
7.3 INFLUENZA 145
7.3.1 RISING NEED FOR IMMUNIZATION AGAINST VIRAL INFECTIONS
TO DRIVE MARKET 145
7.4 COMBINATION VACCINES 149
7.4.1 GROWING DEMAND FOR ALL-IN-ONE VACCINES TO DRIVE MARKET GROWTH 149
7.5 HPV 153
7.5.1 RISING FOCUS ON CERVICAL CANCER PREVENTION TO DRIVE HPV VACCINE UPTAKE 153
7.6 MENINGOCOCCAL DISEASE 157
7.6.1 INCREASING INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS TO SUPPORT MARKET GROWTH 157
7.7 HERPES ZOSTER 161
7.7.1 RISING AGING POPULATION TO DRIVE DEMAND FOR HERPES ZOSTER VACCINES 161
7.8 ROTAVIRUS 164
7.8.1 RISING INFANT IMMUNIZATION PROGRAMS TO DRIVE ROTAVIRUS VACCINE MARKET GROWTH 164
7.9 MMR 167
7.9.1 RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA TO BOOST DEMAND 167
7.10 VARICELLA 171
7.10.1 INCREASING PROMOTION OF IMMUNIZATION PROGRAMS TO SUPPORT MARKET GROWTH 171
7.11 HEPATITIS 174
7.11.1 LOW SOCIO-ECONOMIC STANDARDS OF LIVING AND HIGH CONTAMINATION IN DRINKING WATER TO DRIVE MARKET 174
7.12 DTP 177
7.12.1 STRONG INTEGRATION INTO NATIONAL IMMUNIZATION PROGRAMS TO SUSTAIN DTP VACCINE DEMAND 177
7.13 POLIO 181
7.13.1 INCREASING GOVERNMENT INITIATIVES AND IMMUNIZATION PROGRAMS TO DRIVE MARKET 181
7.14 RSV 184
7.14.1 STRONG PRODUCT PIPELINE AND NEW PRODUCT LAUNCHES TO PROPEL MARKET GROWTH 184
7.15 COVID-19 187
7.15.1 DECLINING DEMAND DUE TO HIGH POPULATION COVERAGE AND REDUCED SEVERITY OF VARIANTS TO SLOW DOWN MARKET GROWTH 187
7.16 OTHER DISEASE INDICATIONS 190
8 VACCINES MARKET, BY TECHNOLOGY 194
8.1 INTRODUCTION 195
8.2 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY 195
8.2.1 CONJUGATE VACCINES 196
8.2.1.1 Increasing public-private partnerships to drive market growth 196
8.2.2 RECOMBINANT VACCINES 199
8.2.2.1 Low post-vaccination reactions and reduced need for booster doses to drive market 199
8.2.3 INACTIVATED & SUBUNIT VACCINES 202
8.2.3.1 Ease of storage and transportation to support growth 202
8.2.4 LIVE ATTENUATED VACCINES 206
8.2.4.1 High cost of storage and limited financial resources of distributors to restrain market 206
8.2.5 TOXOID VACCINES 210
8.2.5.1 Rising prevalence of bacterial infections among infants and children to drive market 210
8.2.6 OTHER VACCINES 214
8.3 COVID-19 VACCINES MARKET, BY TECHNOLOGY 217
8.3.1 MRNA VACCINES 218
8.3.1.1 Increasing focus on mRNA vaccine development to drive market 218
8.3.2 VIRAL VECTOR VACCINES 221
8.3.2.1 Rising investment in vaccine development to drive market 221
8.3.3 OTHER COVID-19 VACCINES 224
9 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE 227
9.1 INTRODUCTION 228
9.2 MULTIVALENT VACCINES 228
9.2.1 INCREASED NEED FOR IMMUNIZATION AND COST-EFFECTIVENESS TO DRIVE MARKET 228
9.3 MONOVALENT VACCINES 232
9.3.1 RISING R&D INVESTMENTS AND PREVALENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH 232
10 VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION 237
10.1 INTRODUCTION 238
10.2 INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION 238
10.2.1 EASE OF ABSORPTION AND BETTER IMMUNE RESPONSE TO DRIVE ADOPTION 238
10.3 ORAL ADMINISTRATION 242
10.3.1 REDUCED RISK OF BLOOD-TRANSMITTED INFECTIONS TO DRIVE ADOPTION 242
10.4 OTHER ROUTES OF ADMINISTRATION 245
11 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER 249
11.1 INTRODUCTION 250
11.2 ADULT VACCINES 250
11.2.1 ADULT VACCINES TO COMMAND LARGER MARKET SHARE
DURING FORECAST PERIOD 250
11.3 PEDIATRIC VACCINES 253
11.3.1 SUPPORT FROM GOVERNMENT AND NON-GOVERNMENT
BODIES TO DRIVE MARKET 253
12 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION 257
12.1 INTRODUCTION 258
12.2 NORTH AMERICA 258
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 259
12.2.2 US 263
12.2.2.1 US to dominate North American market during forecast period 263
12.2.3 CANADA 266
12.2.3.1 High incidence of infectious diseases to drive market growth 266
12.3 EUROPE 269
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 270
12.3.2 GERMANY 274
12.3.2.1 Significant R&D investments and growing biotechnology industry to drive market 274
12.3.3 UK 277
12.3.3.1 Launch of new products and increased funding by government and non-government organizations to drive market 277
12.3.4 FRANCE 280
12.3.4.1 Favorable government initiatives for mass immunization to drive market 280
12.3.5 ITALY 283
12.3.5.1 Higher investments by companies for increased production capacities to drive market 283
12.3.6 SPAIN 286
12.3.6.1 Rising investments in vaccine development by private organizations to drive market 286
12.3.7 REST OF EUROPE 289
12.4 ASIA PACIFIC 293
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 293
12.4.2 CHINA 298
12.4.2.1 China to hold largest share of APAC vaccines market 298
12.4.3 JAPAN 300
12.4.3.1 Favorable government initiatives to support market growth 300
12.4.4 INDIA 305
12.4.4.1 Increasing government initiatives and development of new and improved vaccines to drive market 305
12.4.5 SOUTH KOREA 307
12.4.5.1 Strong government strategies for improved vaccine hubs to drive market 307
12.4.6 REST OF ASIA PACIFIC 310
12.5 LATIN AMERICA 314
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 314
12.5.2 BRAZIL 317
12.5.2.1 Rising focus on immunization programs to drive market 317
12.5.3 MEXICO 321
12.5.3.1 Trained workforce and ethnically varied population base for clinical trials to propel market growth 321
12.5.4 REST OF LATIN AMERICA 323
12.6 MIDDLE EAST 327
12.6.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 327
12.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 327
12.7 AFRICA 331
12.7.1 AVAILABILITY OF FUNDS AND GRANTS FROM DEVELOPED ECONOMIES TO DRIVE MARKET 331
12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 331
13 COMPETITIVE LANDSCAPE 335
13.1 INTRODUCTION 335
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 335
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN VACCINES MARKET 335
13.3 REVENUE ANALYSIS, 2020–2024 338
13.4 MARKET SHARE ANALYSIS, 2024 339
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 341
13.5.1 STARS 342
13.5.2 EMERGING LEADERS 342
13.5.3 PERVASIVE PLAYERS 342
13.5.4 PARTICIPANTS 342
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 344
13.5.5.1 Company footprint 344
13.5.5.2 Region footprint 345
13.5.5.3 Technology footprint 346
13.5.5.4 Type footprint 347
13.5.5.5 Route of administration footprint 348
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 349
13.6.1 PROGRESSIVE COMPANIES 349
13.6.2 RESPONSIVE COMPANIES 349
13.6.3 DYNAMIC COMPANIES 349
13.6.4 STARTING BLOCKS 349
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES 351
13.6.5.1 Detailed list of key startups/SMEs 351
13.6.5.2 Competitive benchmarking of key startups/SMEs 352
13.7 COMPANY VALUATION & FINANCIAL METRICS 353
13.7.1 FINANCIAL METRICS 353
13.7.2 COMPANY VALUATION 353
13.8 BRAND/PRODUCT COMPARISON 354
13.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS 354
13.9 COMPETITIVE SCENARIO 355
13.9.1 PRODUCT LAUNCHES & APPROVALS 355
13.9.2 DEALS 356
13.9.3 EXPANSIONS 357
14 COMPANY PROFILES 358
14.1 KEY PLAYERS 358
14.1.1 GSK PLC 358
14.1.1.1 Business overview 358
14.1.1.2 Products offered 359
14.1.1.3 Recent developments 362
14.1.1.3.1 Product launches & approvals 362
14.1.1.3.2 Deals 363
14.1.1.3.3 Expansions 364
14.1.1.4 MnM view 364
14.1.1.4.1 Key strengths 364
14.1.1.4.2 Strategic choices 364
14.1.1.4.3 Weaknesses & competitive threats 364
14.1.2 MERCK & CO., INC. 365
14.1.2.1 Business overview 365
14.1.2.2 Products offered 366
14.1.2.3 Recent developments 368
14.1.2.3.1 Product approvals 368
14.1.2.3.2 Deals 369
14.1.2.3.3 Expansions 369
14.1.2.4 MnM view 370
14.1.2.4.1 Key strengths 370
14.1.2.4.2 Strategic choices 370
14.1.2.4.3 Weaknesses & competitive threats 370
14.1.3 PFIZER INC. 371
14.1.3.1 Business overview 371
14.1.3.2 Products offered 372
14.1.3.3 Recent developments 374
14.1.3.3.1 Product approvals 374
14.1.3.3.2 Deals 376
14.1.3.4 MnM view 376
14.1.3.4.1 Key strengths 376
14.1.3.4.2 Strategic choices 376
14.1.3.4.3 Weaknesses & competitive threats 376
14.1.4 SANOFI 377
14.1.4.1 Business overview 377
14.1.4.2 Products offered 378
14.1.4.3 Recent developments 380
14.1.4.3.1 Product approvals 380
14.1.4.3.2 Deals 380
14.1.4.3.3 Expansions 381
14.1.4.3.4 Other developments 382
14.1.4.4 MnM view 382
14.1.4.4.1 Key strengths 382
14.1.4.4.2 Strategic choices 382
14.1.4.4.3 Weaknesses & competitive threats 382
14.1.5 CSL 383
14.1.5.1 Business overview 383
14.1.5.2 Products offered 385
14.1.5.3 Recent developments 385
14.1.5.3.1 Product approvals 385
14.1.5.3.2 Deals 386
14.1.5.3.3 Expansions 387
14.1.5.4 MnM view 387
14.1.5.4.1 Key strengths 387
14.1.5.4.2 Strategic choices 387
14.1.5.4.3 Weaknesses & competitive threats 387
14.1.6 EMERGENT 388
14.1.6.1 Business overview 388
14.1.6.2 Products offered 390
14.1.6.3 Recent developments 391
14.1.6.3.1 Product approvals 391
14.1.6.3.2 Other developments 391
14.1.7 JOHNSON & JOHNSON SERVICES, INC. 393
14.1.7.1 Business overview 393
14.1.7.2 Products offered 394
14.1.7.3 Recent developments 395
14.1.7.3.1 Deals 395
14.1.8 ASTRAZENECA 396
14.1.8.1 Business overview 396
14.1.8.2 Products offered 397
14.1.8.3 Recent developments 398
14.1.8.3.1 Deals 398
14.1.8.3.2 Expansions 398
14.1.8.3.3 Other developments 399
14.1.9 SERUM INSTITUTE OF INDIA PVT., LTD. 400
14.1.9.1 Business overview 400
14.1.9.2 Products offered 400
14.1.9.3 Recent developments 403
14.1.9.3.1 Product launches & approvals 403
14.1.9.3.2 Deals 404
14.1.9.3.3 Expansions 404
14.1.10 BAVARIAN NORDIC 405
14.1.10.1 Business overview 405
14.1.10.2 Products offered 406
14.1.10.3 Recent developments 407
14.1.10.3.1 Product approvals 407
14.1.10.3.2 Deals 408
14.1.10.3.3 Other developments 410
14.1.11 MITSUBISHI TANABE PHARMA CORPORATION 411
14.1.11.1 Business overview 411
14.1.11.2 Products offered 411
14.1.11.3 Recent developments 412
14.1.11.3.1 Product launches & approvals 412
14.1.11.3.2 Deals 412
14.1.12 DAIICHI SANKYO COMPANY, LIMITED 413
14.1.12.1 Business overview 413
14.1.12.2 Products offered 414
14.1.12.3 Recent developments 415
14.1.12.3.1 Deals 415
14.1.13 PANACEA BIOTEC 416
14.1.13.1 Business overview 416
14.1.13.2 Products offered 417
14.1.13.3 Recent developments 418
14.1.13.3.1 Deals 418
14.1.14 BIOLOGICAL E LIMITED 419
14.1.14.1 Business overview 419
14.1.14.2 Products offered 419
14.1.14.3 Recent developments 421
14.1.14.3.1 Product approvals 421
14.1.14.3.2 Deals 422
14.1.14.3.3 Other developments 422
14.1.15 BHARAT BIOTECH 423
14.1.15.1 Business overview 423
14.1.15.2 Products offered 423
14.1.15.3 Recent developments 424
14.1.15.3.1 Product launches & approvals 424
14.1.15.3.2 Deals 425
14.1.16 NOVAVAX 426
14.1.16.1 Business overview 426
14.1.16.2 Products offered 427
14.1.16.3 Recent developments 427
14.1.16.3.1 Product approvals 427
14.1.17 INOVIO PHARMACEUTICALS 430
14.1.17.1 Business overview 430
14.1.17.2 Products offered 431
14.1.17.3 Recent developments 431
14.1.17.3.1 Other developments 431
14.2 OTHER PLAYERS 432
14.2.1 SINOVAC 432
14.2.2 INCEPTA PHARMACEUTICALS LTD. 433
14.2.3 VALNEVA SE 435
14.2.4 VBI VACCINE INC. 436
14.2.5 BIO FARMA 437
14.2.6 MICROGEN 439
14.2.7 ZHI FEI BIOLOGICAL 440
14.2.8 INDIAN IMMUNOLOGICALS LIMITED 441
15 APPENDIX 442
15.1 DISCUSSION GUIDE 442
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 446
15.3 CUSTOMIZATION OPTIONS 448
15.4 RELATED REPORTS 448
15.5 AUTHOR DETAILS 449
LIST OF TABLES
TABLE 1 VACCINES MARKET: INCLUSIONS & EXCLUSIONS 40
TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 53
TABLE 3 VACCINES MARKET: RISK ASSESSMENT ANALYSIS 57
TABLE 4 VACCINES MARKET: STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES 69
TABLE 5 VACCINES MARKET: EMERGING BUSINESS MODELS & TARGET SEGMENTS 70
TABLE 6 VACCINES MARKET: IMPACT ANALYSIS 74
TABLE 7 NIH FUNDING FOR VACCINE RESEARCH, 2020–2024 (USD MILLION) 79
TABLE 8 MAJOR COST DRIVERS AND IMPACT ON COST OF GOODS SOLD (COGS) 80
TABLE 9 NOTABLE CANCER VACCINES IN CLINICAL TRIALS 83
TABLE 10 AVERAGE SELLING PRICE TREND OF PEDIATRIC VACCINES, BY KEY PLAYER,
2023–2025 (USD) 88
TABLE 11 AVERAGE SELLING PRICE TREND OF ADULT VACCINES, BY KEY PLAYER,
2023–2025 (USD) 89
TABLE 12 AVERAGE SELLING PRICE TREND OF VACCINES, BY REGION, 2021–2023 (USD) 92
TABLE 13 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR RSV 99
TABLE 14 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR PNEUMOCOCCAL DISEASE 102
TABLE 15 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR INFLUENZA 104
TABLE 16 KEY PIPELINE VACCINES: GSK PLC 105
TABLE 17 KEY PIPELINE VACCINES: MERCK & CO., INC. 106
TABLE 18 KEY PIPELINE VACCINES: PFIZER INC. 106
TABLE 19 KEY PIPELINE VACCINES: SANOFI S.A. 106
TABLE 20 VACCINES MARKET: ROLE IN ECOSYSTEM 107
TABLE 21 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 109
TABLE 22 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 110
TABLE 23 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 111
TABLE 24 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 111
TABLE 25 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 112
TABLE 26 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 112
TABLE 27 IMPORT VALUE FOR HS CODE 300220, 2020–2024 (USD THOUSAND) 114
TABLE 28 IMPORT VOLUME FOR HS CODE 300220, 2020–2024 (TONS) 115
TABLE 29 EXPORT VALUE FOR HS CODE 300220, 2020–2024 (USD THOUSAND) 116
TABLE 30 EXPORT VOLUME FOR HS CODE 300220, 2020–2024 (TONS) 117
TABLE 31 VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS 118
TABLE 32 VACCINES MARKET: INDICATIVE LIST OF PATENTS, 2025 122
TABLE 33 VACCINES MARKET: LIST OF CONFERENCES & EVENTS, 2025–2026 123
TABLE 34 BUYING CRITERIA FOR VACCINES, BY END USER 125
TABLE 35 KEY COMPANIES IMPLEMENTING AI 128
TABLE 36 US-ADJUSTED RECIPROCAL TARIFF RATES 129
TABLE 37 NUMBER OF VACCINES DELIVERED BY UNICEF, 2023–2025 133
TABLE 38 WHO VACCINE PURCHASE DATABASE, BY PROCUREMENT MECHANISM,
2021–2023 134
TABLE 39 WHO VACCINE PURCHASE DATABASE, BY MANUFACTURER, 2021–2023 134
TABLE 40 WHO VACCINE PURCHASE DATABASE, BY INDICATION, 2021–2023 135
TABLE 41 WHO VACCINE PURCHASE DATABASE, BY REGION, 2021–2023 136
TABLE 42 VACCINE PRODUCTION CAPACITY, BY KEY PLAYER, 2024 138
TABLE 43 VACCINES MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION) 140
TABLE 44 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL DISEASE VACCINES 142
TABLE 45 PNEUMOCOCCAL DISEASE VACCINES MARKET, BY REGION,
2023–2030 (USD MILLION) 142
TABLE 46 NORTH AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 47 EUROPE: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 143
TABLE 48 ASIA PACIFIC: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 144
TABLE 49 LATIN AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 50 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES 146
TABLE 51 INFLUENZA VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 147
TABLE 52 NORTH AMERICA: INFLUENZA VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 147
TABLE 53 EUROPE: INFLUENZA VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 148
TABLE 54 ASIA PACIFIC: INFLUENZA VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 148
TABLE 55 LATIN AMERICA: INFLUENZA VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 149
TABLE 56 LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES 150
TABLE 57 COMBINATION VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 151
TABLE 58 NORTH AMERICA: COMBINATION VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 151
TABLE 59 EUROPE: COMBINATION VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 152
TABLE 60 ASIA PACIFIC: COMBINATION VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 152
TABLE 61 LATIN AMERICA: COMBINATION VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 153
TABLE 62 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES 154
TABLE 63 HPV VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 155
TABLE 64 NORTH AMERICA: HPV VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 155
TABLE 65 EUROPE: HPV VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 66 ASIA PACIFIC: HPV VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 67 LATIN AMERICA: HPV VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 157
TABLE 68 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES 158
TABLE 69 MENINGOCOCCAL DISEASE VACCINES MARKET, BY REGION,
2023–2030 (USD MILLION) 158
TABLE 70 NORTH AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 71 EUROPE: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 159
TABLE 72 ASIA PACIFIC: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 73 LATIN AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 74 LIST OF COMMERCIALLY AVAILABLE HERPES ZOSTER VACCINES 162
TABLE 75 HERPES ZOSTER VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 162
TABLE 76 NORTH AMERICA: HERPES ZOSTER VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 162
TABLE 77 EUROPE: HERPES ZOSTER VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 163
TABLE 78 ASIA PACIFIC: HERPES ZOSTER VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 163
TABLE 79 LATIN AMERICA: HERPES ZOSTER VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 164
TABLE 80 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES 164
TABLE 81 ROTAVIRUS VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 165
TABLE 82 NORTH AMERICA: ROTAVIRUS VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 165
TABLE 83 EUROPE: ROTAVIRUS VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 166
TABLE 84 ASIA PACIFIC: ROTAVIRUS VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 166
TABLE 85 LATIN AMERICA: ROTAVIRUS VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 167
TABLE 86 TOP 10 COUNTRIES WITH MEASLES OUTBREAKS, JANUARY 2025–JULY 2025 168
TABLE 87 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES 168
TABLE 88 MMR VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 169
TABLE 89 NORTH AMERICA: MMR VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 169
TABLE 90 EUROPE: MMR VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 91 ASIA PACIFIC: MMR VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 92 LATIN AMERICA: MMR VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 171
TABLE 93 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES 172
TABLE 94 VARICELLA VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 172
TABLE 95 NORTH AMERICA: VARICELLA VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 172
TABLE 96 EUROPE: VARICELLA VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 173
TABLE 97 ASIA PACIFIC: VARICELLA VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 173
TABLE 98 LATIN AMERICA: VARICELLA VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 174
TABLE 99 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES 175
TABLE 100 HEPATITIS VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 175
TABLE 101 NORTH AMERICA: HEPATITIS VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 176
TABLE 102 EUROPE: HEPATITIS VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 176
TABLE 103 ASIA PACIFIC: HEPATITIS VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 177
TABLE 104 LATIN AMERICA: HEPATITIS VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 177
TABLE 105 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES 178
TABLE 106 DTP VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 178
TABLE 107 NORTH AMERICA: DTP VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 179
TABLE 108 EUROPE: DTP VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 179
TABLE 109 ASIA PACIFIC: DTP VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 180
TABLE 110 LATIN AMERICA: DTP VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 180
TABLE 111 POLIO VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 181
TABLE 112 NORTH AMERICA: POLIO VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 182
TABLE 113 EUROPE: POLIO VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 182
TABLE 114 ASIA PACIFIC: POLIO VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 183
TABLE 115 LATIN AMERICA: POLIO VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 183
TABLE 116 RSV VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 185
TABLE 117 NORTH AMERICA: RSV VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 185
TABLE 118 EUROPE: RSV VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 186
TABLE 119 ASIA PACIFIC: RSV VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 186
TABLE 120 LATIN AMERICA: RSV VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 187
TABLE 121 COVID-19 VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 188
TABLE 122 NORTH AMERICA: COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 188
TABLE 123 EUROPE: COVID-19 VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 189
TABLE 124 ASIA PACIFIC: COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 189
TABLE 125 LATIN AMERICA: COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 190
TABLE 126 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS 190
TABLE 127 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION,
2023–2030 (USD MILLION) 191
TABLE 128 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 191
TABLE 129 EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 192
TABLE 130 ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 192
TABLE 131 LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 193
TABLE 132 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY,
2023–2030 (USD MILLION) 195
TABLE 133 CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2023–2030 (USD MILLION) 197
TABLE 134 NORTH AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 197
TABLE 135 EUROPE: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 198
TABLE 136 ASIA PACIFIC: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 198
TABLE 137 LATIN AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 199
TABLE 138 EXAMPLES OF RECOMBINANT VACCINES 200
TABLE 139 RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2023–2030 (USD MILLION) 200
TABLE 140 NORTH AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 201
TABLE 141 EUROPE: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 201
TABLE 142 ASIA PACIFIC: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 202
TABLE 143 LATIN AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 202
TABLE 144 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES 203
TABLE 145 INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2023–2030 (USD MILLION) 204
TABLE 146 NORTH AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 204
TABLE 147 EUROPE: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 205
TABLE 148 ASIA PACIFIC: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 205
TABLE 149 LATIN AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET
(EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 206
TABLE 150 EXAMPLES OF LIVE ATTENUATED VACCINES 207
TABLE 151 LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2023–2030 (USD MILLION) 208
TABLE 152 NORTH AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 208
TABLE 153 EUROPE: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 209
TABLE 154 ASIA PACIFIC: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 209
TABLE 155 LATIN AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 210
TABLE 156 EXAMPLES OF TOXOID VACCINES 211
TABLE 157 TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION,
2023–2030 (USD MILLION) 211
TABLE 158 NORTH AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 212
TABLE 159 EUROPE: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 212
TABLE 160 ASIA PACIFIC: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 213
TABLE 161 LATIN AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 213
TABLE 162 OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION,
2023–2030 (USD MILLION) 215
TABLE 163 NORTH AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 215
TABLE 164 EUROPE: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 216
TABLE 165 ASIA PACIFIC: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 216
TABLE 166 LATIN AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 217
TABLE 167 COVID-19 VACCINES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 217
TABLE 168 MRNA COVID-19 VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 219
TABLE 169 NORTH AMERICA: MRNA COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 219
TABLE 170 EUROPE: MRNA COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 220
TABLE 171 ASIA PACIFIC: MRNA COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 220
TABLE 172 LATIN AMERICA: MRNA COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 221
TABLE 173 VIRAL VECTOR COVID-19 VACCINES MARKET, BY REGION,
2023–2030 (USD MILLION) 222
TABLE 174 NORTH AMERICA: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 222
TABLE 175 EUROPE: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 223
TABLE 176 ASIA PACIFIC: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 223
TABLE 177 LATIN AMERICA: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 224
TABLE 178 OTHER COVID-19 VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 224
TABLE 179 NORTH AMERICA: OTHER COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 225
TABLE 180 EUROPE: OTHER COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 225
TABLE 181 ASIA PACIFIC: OTHER COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 226
TABLE 182 LATIN AMERICA: OTHER COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 226
TABLE 183 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 228
TABLE 184 EXAMPLES OF MULTIVALENT VACCINES 229
TABLE 185 MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2023–2030 (USD MILLION) 230
TABLE 186 NORTH AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 230
TABLE 187 EUROPE: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 231
TABLE 188 ASIA PACIFIC: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 231
TABLE 189 LATIN AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 232
TABLE 190 EXAMPLES OF MONOVALENT VACCINES 233
TABLE 191 MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2023–2030 (USD MILLION) 234
TABLE 192 NORTH AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 234
TABLE 193 EUROPE: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 235
TABLE 194 ASIA PACIFIC: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 235
TABLE 195 LATIN AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 236
TABLE 196 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 238
TABLE 197 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR &
SUBCUTANEOUS ADMINISTRATION 239
TABLE 198 VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2023–2030 (USD MILLION) 240
TABLE 199 NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2023–2030 (USD MILLION) 240
TABLE 200 EUROPE: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2023–2030 (USD MILLION) 241
TABLE 201 ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2023–2030 (USD MILLION) 241
TABLE 202 LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2023–2030 (USD MILLION) 242
TABLE 203 VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2023–2030 (USD MILLION) 243
TABLE 204 NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 243
TABLE 205 EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 244
TABLE 206 ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING
COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 244
TABLE 207 LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 245
TABLE 208 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING
COVID-19 VACCINES), BY REGION, 2023–2030 (USD MILLION) 246
TABLE 209 NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 246
TABLE 210 EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 247
TABLE 211 ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 247
TABLE 212 LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 248
TABLE 213 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER,
2023–2030 (USD MILLION) 250
TABLE 214 ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION,
2023–2030 (USD MILLION) 251
TABLE 215 NORTH AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 252
TABLE 216 EUROPE: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 252
TABLE 217 ASIA PACIFIC: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 253
TABLE 218 LATIN AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 253
TABLE 219 PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2023–2030 (USD MILLION) 254
TABLE 220 NORTH AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 255
TABLE 221 EUROPE: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 255
TABLE 222 ASIA PACIFIC: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 256
TABLE 223 LATIN AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 256
TABLE 224 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION,
2023–2030 (USD MILLION) 258
TABLE 225 NORTH AMERICA: KEY MACROINDICATORS 259
TABLE 226 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 260
TABLE 227 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2023–2030 (USD MILLION) 261
TABLE 228 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2023–2030 (USD MILLION) 261
TABLE 229 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2023–2030 (USD MILLION) 262
TABLE 230 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 263
TABLE 231 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2023–2030 (USD MILLION) 263
TABLE 232 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 264
TABLE 233 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 265
TABLE 234 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 265
TABLE 235 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 266
TABLE 236 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER,
2023–2030 (USD MILLION) 266
TABLE 237 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 267
TABLE 238 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 268
TABLE 239 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 268
TABLE 240 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 269
TABLE 241 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 269
TABLE 242 EUROPE: KEY MACROINDICATORS 270
TABLE 243 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 271
TABLE 244 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 271
TABLE 245 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 272
TABLE 246 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 272
TABLE 247 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 273
TABLE 248 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 273
TABLE 249 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2023–2030 (USD MILLION) 275
TABLE 250 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 275
TABLE 251 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 276
TABLE 252 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 277
TABLE 253 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 277
TABLE 254 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 278
TABLE 255 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 279
TABLE 256 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 279
TABLE 257 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 280
TABLE 258 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER,
2023–2030 (USD MILLION) 280
TABLE 259 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 281
TABLE 260 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 282
TABLE 261 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 282
TABLE 262 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 283
TABLE 263 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2023–2030 (USD MILLION) 283
TABLE 264 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 284
TABLE 265 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 284
TABLE 266 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 285
TABLE 267 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 286
TABLE 268 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 286
TABLE 269 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 287
TABLE 270 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 287
TABLE 271 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 288
TABLE 272 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 289
TABLE 273 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 289
TABLE 274 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2023–2030 (USD MILLION) 290
TABLE 275 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TYPE, 2023–2030 (USD MILLION) 290
TABLE 276 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2023–2030 (USD MILLION) 291
TABLE 277 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 292
TABLE 278 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2023–2030 (USD MILLION) 292
TABLE 279 ASIA PACIFIC: KEY MACROINDICATORS 294
TABLE 280 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 295
TABLE 281 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2023–2030 (USD MILLION) 295
TABLE 282 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2023–2030 (USD MILLION) 296
TABLE 283 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 296
TABLE 284 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 297
TABLE 285 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2023–2030 (USD MILLION) 297
TABLE 286 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 298
TABLE 287 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 299
TABLE 288 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 299
TABLE 289 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 300
TABLE 290 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 300
TABLE 291 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 302
TABLE 292 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 302
TABLE 293 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 303
TABLE 294 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 304
TABLE 295 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 304
TABLE 296 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 305
TABLE 297 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 306
TABLE 298 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 306
TABLE 299 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 307
TABLE 300 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 307
TABLE 301 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2023–2030 (USD MILLION) 308
TABLE 302 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2023–2030 (USD MILLION) 309
TABLE 303 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2023–2030 (USD MILLION) 309
TABLE 304 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 310
TABLE 305 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2023–2030 (USD MILLION) 310
TABLE 306 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2023–2030 (USD MILLION) 311
TABLE 307 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TYPE, 2023–2030 (USD MILLION) 312
TABLE 308 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2023–2030 (USD MILLION) 312
TABLE 309 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 313
TABLE 310 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2023–2030 (USD MILLION) 313
TABLE 311 LATIN AMERICA: KEY MACROINDICATORS 314
TABLE 312 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 315
TABLE 313 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2023–2030 (USD MILLION) 315
TABLE 314 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2023–2030 (USD MILLION) 316
TABLE 315 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2023–2030 (USD MILLION) 316
TABLE 316 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 317
TABLE 317 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2023–2030 (USD MILLION) 317
TABLE 318 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 318
TABLE 319 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 318
TABLE 320 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 319
TABLE 321 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 320
TABLE 322 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 320
TABLE 323 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 321
TABLE 324 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 322
TABLE 325 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 322
TABLE 326 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 323
TABLE 327 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 323
TABLE 328 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 324
TABLE 329 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2023–2030 (USD MILLION) 324
TABLE 330 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 325
TABLE 331 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 326
TABLE 332 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 326
TABLE 333 MIDDLE EAST: KEY MACROINDICATORS 327
TABLE 334 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2023–2030 (USD MILLION) 328
TABLE 335 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2023–2030 (USD MILLION) 328
TABLE 336 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 329
TABLE 337 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 330
TABLE 338 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2023–2030 (USD MILLION) 330
TABLE 339 AFRICA: KEY MACROINDICATORS 331
TABLE 340 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 332
TABLE 341 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 332
TABLE 342 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 333
TABLE 343 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 334
TABLE 344 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 334
TABLE 345 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VACCINES MARKET, JANUARY 2022−AUGUST 2025 335
TABLE 346 VACCINES MARKET: DEGREE OF COMPETITION 340
TABLE 347 VACCINES MARKET: REGION FOOTPRINT 345
TABLE 348 VACCINES MARKET: TECHNOLOGY FOOTPRINT 346
TABLE 349 VACCINES MARKET: TYPE FOOTPRINT 347
TABLE 350 VACCINES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 348
TABLE 351 VACCINES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 351
TABLE 352 VACCINES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 352
TABLE 353 VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–AUGUST 2025 355
TABLE 354 VACCINES MARKET: DEALS, JANUARY 2022–AUGUST 2025 356
TABLE 355 VACCINES MARKET: EXPANSIONS, JANUARY 2022–AUGUST 2025 357
TABLE 356 GSK PLC: COMPANY OVERVIEW 358
TABLE 357 GSK PLC: PRODUCTS OFFERED 359
TABLE 358 GSK PLC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025 362
TABLE 359 GSK PLC: DEALS, JANUARY 2022–AUGUST 2025 363
TABLE 360 GSK PLC: EXPANSIONS, JANUARY 2022–AUGUST 2025 364
TABLE 361 MERCK & CO., INC.: COMPANY OVERVIEW 365
TABLE 362 MERCK & CO., INC.: PRODUCTS OFFERED 366
TABLE 363 MERCK & CO., INC.: PRODUCT APPROVALS, JANUARY 2022–AUGUST 2025 368
TABLE 364 MERCK & CO., INC.: DEALS, JANUARY 2022–AUGUST 2025 369
TABLE 365 MERCK & CO., INC.: EXPANSIONS, JANUARY 2022–AUGUST 2025 369
TABLE 366 PFIZER INC.: COMPANY OVERVIEW 371
TABLE 367 PFIZER INC.: PRODUCTS OFFERED 372
TABLE 368 PFIZER INC.: PRODUCT APPROVALS, JANUARY 2022–AUGUST 2025 374
TABLE 369 PFIZER INC.: DEALS, JANUARY 2022–AUGUST 2025 376
TABLE 370 SANOFI: COMPANY OVERVIEW 377
TABLE 371 SANOFI: PRODUCTS OFFERED 378
TABLE 372 SANOFI: PRODUCT APPROVALS, JANUARY 2022–AUGUST 2025 380
TABLE 373 SANOFI: DEALS, JANUARY 2022–AUGUST 2025 380
TABLE 374 SANOFI: EXPANSIONS, JANUARY 2022–AUGUST 2025 381
TABLE 375 SANOFI: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 382
TABLE 376 CSL: COMPANY OVERVIEW 383
TABLE 377 CSL: PRODUCTS OFFERED 385
TABLE 378 CSL: PRODUCT APPROVALS, JANUARY 2022–AUGUST 2025 385
TABLE 379 CSL: DEALS, JANUARY 2022–AUGUST 2025 386
TABLE 380 CSL: EXPANSIONS, JANUARY 2022–AUGUST 2025 387
TABLE 381 EMERGENT: COMPANY OVERVIEW 388
TABLE 382 EMERGENT: PRODUCTS OFFERED 390
TABLE 383 EMERGENT: PRODUCT APPROVALS, JANUARY 2022–AUGUST 2025 391
TABLE 384 EMERGENT: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 391
TABLE 385 JOHNSON & JOHNSON SERVICES INC.: COMPANY OVERVIEW 393
TABLE 386 JOHNSON & JOHNSON SERVICES INC.: PRODUCTS OFFERED 394
TABLE 387 JOHNSON & JOHNSON SERVICES INC.: DEALS, JANUARY 2022–AUGUST 2025 395
TABLE 388 ASTRAZENECA: COMPANY OVERVIEW 396
TABLE 389 ASTRAZENECA: PRODUCTS OFFERED 397
TABLE 390 ASTRAZENECA: DEALS, JANUARY 2022–AUGUST 2025 398
TABLE 391 ASTRAZENECA: EXPANSIONS, JANUARY 2022–AUGUST 2025 398
TABLE 392 ASTRAZENECA: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 399
TABLE 393 SERUM INSTITUTE OF INDIA PVT., LTD.: COMPANY OVERVIEW 400
TABLE 394 SERUM INSTITUTE OF INDIA PVT., LTD.: PRODUCTS OFFERED
(SUPPLIED OVERSEAS) 400
TABLE 395 SERUM INSTITUTE OF INDIA PVT., LTD.: PRODUCTS OFFERED (SUPPLIED IN INDIA) 402
TABLE 396 SERUM INSTITUTE OF INDIA PVT., LTD.: PRODUCTS LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025 403
TABLE 397 SERUM INSTITUTE OF INDIA PVT., LTD.: DEALS, JANUARY 2022–AUGUST 2025 404
TABLE 398 SERUM INSTITUTE OF INDIA PVT., LTD.: EXPANSIONS,
JANUARY 2022–AUGUST 2025 404
TABLE 399 BAVARIAN NORDIC: COMPANY OVERVIEW 405
TABLE 400 BAVARIAN NORDIC: PRODUCTS OFFERED 406
TABLE 401 BAVARIAN NORDIC: PRODUCT APPROVALS, JANUARY 2022–AUGUST 2025 407
TABLE 402 BAVARIAN NORDIC: DEALS, JANUARY 2022–AUGUST 2025 408
TABLE 403 BAVARIAN NORDIC: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 410
TABLE 404 MITSUBISHI TANABE PHARMA CORPORATION: COMPANY OVERVIEW 411
TABLE 405 MITSUBISHI TANABE PHARMA CORPORATION: PRODUCTS OFFERED 411
TABLE 406 MITSUBISHI TANABE PHARMA CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025 412
TABLE 407 MITSUBISHI TANABE PHARMA CORPORATION: DEALS,
JANUARY 2022–AUGUST 2025 412
TABLE 408 DAIICHI SANKYO COMPANY, LIMITED: COMPANY OVERVIEW 413
TABLE 409 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS OFFERED 414
TABLE 410 DAIICHI SANKYO COMPANY, LIMITED: DEALS, JANUARY 2022–AUGUST 2025 415
TABLE 411 PANACEA BIOTEC: COMPANY OVERVIEW 416
TABLE 412 PANACEA BIOTEC: PRODUCTS OFFERED 417
TABLE 413 PANACEA BIOTEC: DEALS, JANUARY 2022–AUGUST 2025 418
TABLE 414 BIOLOGICAL E LIMITED: COMPANY OVERVIEW 419
TABLE 415 BIOLOGICAL E LIMITED: PRODUCTS OFFERED (INDIAN MARKET) 419
TABLE 416 BIOLOGICAL E LIMITED: PRODUCTS OFFERED (INTERNATIONAL MARKET) 420
TABLE 417 BIOLOGICAL E LIMITED: PRODUCT APPROVALS, JANUARY 2022–AUGUST 2025 421
TABLE 418 BIOLOGICAL E LIMITED: DEALS, JANUARY 2022–AUGUST 2025 422
TABLE 419 BIOLOGICAL E LIMITED: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 422
TABLE 420 BHARAT BIOTECH: COMPANY OVERVIEW 423
TABLE 421 BHARAT BIOTECH: PRODUCTS OFFERED 423
TABLE 422 BHARAT BIOTECH: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–AUGUST 2025 424
TABLE 423 BHARAT BIOTECH: DEALS, JANUARY 2022–AUGUST 2025 425
TABLE 424 NOVAVAX: COMPANY OVERVIEW 426
TABLE 425 NOVAVAX: PRODUCTS OFFERED 427
TABLE 426 NOVAVAX: PRODUCT APPROVALS, JANUARY 2022–AUGUST 2025 427
TABLE 427 INOVIO PHARMACEUTICALS: COMPANY OVERVIEW 430
TABLE 428 INOVIO PHARMACEUTICALS: PRODUCTS OFFERED 431
TABLE 429 INOVIO PHARMACEUTICALS: OTHER DEVELOPMENTS,
JANUARY 2022–AUGUST 2025 431
TABLE 430 SINOVAC: COMPANY OVERVIEW 432
TABLE 431 INCEPTA PHARMACEUTICALS LTD.: COMPANY OVERVIEW 433
TABLE 432 VALNEVA SE: COMPANY OVERVIEW 435
TABLE 433 VBI VACCINE INC.: COMPANY OVERVIEW 436
TABLE 434 BIO FARMA: COMPANY OVERVIEW 437
TABLE 435 MICROGEN: COMPANY OVERVIEW 439
TABLE 436 ZHI FEI BIOLOGICAL: COMPANY OVERVIEW 440
TABLE 437 INDIAN IMMUNOLOGICALS LIMITED: COMPANY OVERVIEW 441
LIST OF FIGURES
FIGURE 1 VACCINES MARKET SEGMENTATION & REGIONAL SCOPE 39
FIGURE 2 VACCINES MARKET: RESEARCH DESIGN 43
FIGURE 3 VACCINES MARKET: BREAKDOWN OF PRIMARIES (SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 45
FIGURE 4 VACCINES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 46
FIGURE 5 GLOBAL MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS
(BOTTOM-UP APPROACH), 2024 47
FIGURE 6 ILLUSTRATIVE EXAMPLE OF PFIZER INC.: REVENUE SHARE ANALYSIS, 2024 48
FIGURE 7 ILLUSTRATIVE EXAMPLE OF INFLUENZA VACCINES: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2024 49
FIGURE 8 VACCINES MARKET: MARKET SIZE VALIDATION FROM PRIMARY SOURCES 50
FIGURE 9 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 51
FIGURE 10 VACCINES MARKET: CAGR PROJECTION (2025–2030) 53
FIGURE 11 VACCINES MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS 54
FIGURE 12 DATA TRIANGULATION METHODOLOGY 55
FIGURE 13 VACCINES MARKET, BY DISEASE INDICATION, 2025 VS. 2030 (USD MILLION) 58
FIGURE 14 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY,
2025 VS. 2030 (USD MILLION) 59
FIGURE 15 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2025 VS. 2030 (USD MILLION) 60
FIGURE 16 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION) 61
FIGURE 17 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER,
2025 VS. 2030 (USD MILLION) 62
FIGURE 18 REGIONAL SNAPSHOT OF VACCINES MARKET (EXCLUDING COVID-19 VACCINES) 63
FIGURE 19 FOCUS ON VACCINE DEVELOPMENT & LAUNCHES TO PROPEL MARKET GROWTH 66
FIGURE 20 US AND MULTIVALENT VACCINES SEGMENT COMMANDED LARGEST MARKET SHARES IN 2024 67
FIGURE 21 CHINA TO REGISTER HIGHER CAGR DURING FORECAST PERIOD 68
FIGURE 22 VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 73
FIGURE 23 US: NOVEL INFLUENZA A VIRUS CASES, BY SEASON (2010–2011 TO
2023–2024 SEASON) 76
FIGURE 24 MANUFACTURING-RELATED PARAMETERS INCLUDED IN COST MODEL 81
FIGURE 25 US: ESTIMATED NUMBER OF NEW CANCER CASES AND DEATHS BY SITE, 2025 82
FIGURE 26 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 87
FIGURE 27 AVERAGE SELLING PRICE TREND OF VACCINES, BY DISEASE INDICATION,
2023–2025 (USD) 91
FIGURE 28 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES TO CONTRIBUTE MAXIMUM VALUE 97
FIGURE 29 VACCINES MARKET: CLINICAL TRIALS, BY PHASE 98
FIGURE 30 VACCINES MARKET: CLINICAL TRIALS, BY DISEASE INDICATION 99
FIGURE 31 VACCINES MARKET: ECOSYSTEM MARKET MAP 107
FIGURE 32 VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS 118
FIGURE 33 TOP APPLICANTS/OWNERS (COMPANIES) FOR VACCINES PATENTS, 2014–2024 121
FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINES 124
FIGURE 35 KEY BUYING CRITERIA FOR END USERS 125
FIGURE 36 BIOPHARMA MERGER & ACQUISITION (M&A) ACTIVITIES: INVESTMENT & FUNDING SCENARIO, 2020−2024 126
FIGURE 37 VACCINES DEAL ACTIVITIES: INVESTMENT & FUNDING SCENARIO, 2017−2023 126
FIGURE 38 AI USE CASES 128
FIGURE 39 NORTH AMERICA: VACCINES MARKET SNAPSHOT
(EXCLUDING COVID-19 VACCINES) 260
FIGURE 40 ASIA PACIFIC: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES) 294
FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN VACCINES MARKET,
2020–2024 (USD BILLION) 339
FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN VACCINES MARKET (2024) 340
FIGURE 43 VACCINES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 343
FIGURE 44 VACCINES MARKET: COMPANY FOOTPRINT 344
FIGURE 45 VACCINES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 350
FIGURE 46 EV/EBITDA OF KEY VENDORS 353
FIGURE 47 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY VENDORS 353
FIGURE 48 VACCINES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 354
FIGURE 49 GSK PLC: COMPANY SNAPSHOT (2024) 359
FIGURE 50 MERCK & CO., INC.: COMPANY SNAPSHOT (2024) 366
FIGURE 51 PFIZER INC.: COMPANY SNAPSHOT (2024) 372
FIGURE 52 SANOFI: COMPANY SNAPSHOT (2024) 378
FIGURE 53 CSL: COMPANY SNAPSHOT (2024) 384
FIGURE 54 EMERGENT: COMPANY SNAPSHOT (2024) 389
FIGURE 55 JOHNSON & JOHNSON SERVICES INC.: COMPANY SNAPSHOT (2024) 394
FIGURE 56 ASTRAZENECA: COMPANY SNAPSHOT (2024) 397
FIGURE 57 BAVARIAN NORDIC: COMPANY SNAPSHOT (2024) 406
FIGURE 58 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2024) 414
FIGURE 59 PANACEA BIOTEC: COMPANY SNAPSHOT (2024) 416
FIGURE 60 NOVAVAX: COMPANY SNAPSHOT (2024) 426
FIGURE 61 INOVIO PHARMACEUTICALS: COMPANY SNAPSHOT (2024) 430
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 精密林業市場規模、シェア、動向、2030年までの世界予測 2025-11-05
- フィールドサービス管理市場規模、シェア、動向、2030年までの世界予測 2025-11-05
- 採血装置市場規模、シェア、動向、2030年までの世界予測 2025-11-04
- 車載半導体市場規模、シェア、動向、2030年までの世界予測 2025-11-04
- データセンターUPS市場規模、シェア、動向、2030年までの世界予測 2025-10-31